Brief: FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels And Blood Sugar
25/08/2026 19:34
BRIEF-FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels And Blood Sugar Aug 26 (Reuters) - FDA:
FDA AUTHORIZES FIRST WEARABLE DEVICE THAT CONTINUOUSLY MONITORS BOTH KETONE LEVELS AND BLOOD SUGAR
FDA: GRANTED MARKETING AUTHORIZATION TO ABBOTT DIABETES CARE FOR LIBRE DUO 10 DAY THROUGH DE NOVO PREMARKET REVIEW PATHWAY
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement